期刊
ONCOTARGET
卷 7, 期 30, 页码 47252-47264出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.10055
关键词
esophageal cancer; immunohistochemistry; PD-L1; tumor infiltrating lymphocyte; macrophage
资金
- National Cancer Center Hospital East
- Health and Labor Science Research Grant
- Grants-in-Aid for Scientific Research [26460981] Funding Source: KAKEN
Immunotherapy with anti-PD-1 antibody preliminarily showed promising efficacy for treating esophageal squamous cell carcinoma (ESCC). Herein, we used tissue microarrays and immunohistochemically analyzed PD-L1 and various tumor infiltrating immune cells (TIICs) in specimens from 196 ESCC patients who had undergone curative resection without preoperative therapy. PD-L1 expressions in tumor cells (TCs) and TIICs, as well as infiltration of lymphocytes (CD4(+), CD8(+), FOXP3(+), and PD-1(+)) and macrophages (CD68(+) and CD204(+)), were evaluated. PD-L1 was expressed in TCs of 18.4% and in TIICs of 83.3% of these patients. PD-L1 expressions in TCs and TIICs were associated with significant infiltration of various TIIC types, especially CD8+ cells. PD-L1 expressions in both TCs and TIICs were significantly associated with favorable overall survival, and combining their levels enhanced prognostic accuracy. Prognostic impacts of PD-L1 expressions in TCs and TIICs, abundant PD-1+ cell infiltration, a high CD8(+)/FOXP3+ ratio, and the CD8(+)/CD204(+) ratio remained significant after adjusting for clinicopathological factors. In conclusion, PD-L1 expression reflects anti-tumor immunity, and PD-1/PD-L1 expression and the ratio of infiltrating effector to immune suppressor cells have prognostic value. Therapeutic strategies inhibiting the PD-1/PD-L1 signal and immune suppressor cells are anticipated in ESCC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据